compounding HOTLINE

Martin A. Erickson III, RPh
Published Online: Thursday, February 1, 2007

Q: I have worked locum tenens in several different pharmacies, each of which makes various mouthwashes for postirradiation pain and infections. These formulations are FIRST, Malik's, Gillespie's, and Magic Mouthwashes. Isn't there one way to compound each of these preparations? I keep seeing differences among the pharmacies.

A: An advantage of extemporaneous compounding is its flexibility?the pharmacist can tailor therapy to meet a particular patient's requirements. Usually, interaction with the patient and physician is required to accomplish such targeted therapy. The process of developing compounded formulations requires a pharmacist's special knowledge and skills.

"Magic Mouthwash" (for want of a better category name) formulations are as varied as the patients treated and the prescribers who diagnose. For example, postirradiation burns are often treated with a formulation of nystatin, diphenhydramine, lidocaine, and antacid suspension such as Maalox. Sometimes an antibiotic such as tetracycline is added. A number of different regional names are applied to various formulations, and, within a region, variations on the main theme are often found. Stanford Mouthwash and Powell's Mouthwash are 2 such "named formulations," but variations abound.

A central point to consider is that strict adherence to a particular compounded formulation is important to providing consistent care to a particular patient. When a particular formulation appears to provide relief for a patient, that patient should always obtain the same formulation compounded the same way.

Compounding differs from manufacturing?current Good Manufacturing Practices promulgated by the FDA require strict adherence to formulations in manufactured drug products. Extemporaneous compounding is not manufacturing but is the province of the pharmacist. It should be carried out with adherence to principles of pharmacy practice (cf USP 28<795> and <797>).

E-mail your compounding questions to

Mr. Erickson is director of professional affairs at Gallipot Inc.

Latest Articles
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Vertex Pharmaceuticals has received a complete response letter from the FDA for its supplemental new drug application for ivacaftor.
As the only pharmacist serving in Congress, US Representative Earl L. “Buddy” Carter is a critical leader of efforts to pass federal legislation pertinent to pharmacists.
Latest Issues